JP7430636B2 - 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用 - Google Patents

操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用 Download PDF

Info

Publication number
JP7430636B2
JP7430636B2 JP2020530565A JP2020530565A JP7430636B2 JP 7430636 B2 JP7430636 B2 JP 7430636B2 JP 2020530565 A JP2020530565 A JP 2020530565A JP 2020530565 A JP2020530565 A JP 2020530565A JP 7430636 B2 JP7430636 B2 JP 7430636B2
Authority
JP
Japan
Prior art keywords
human
rodent
light chain
gene
gene segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020530565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021505141A5 (enExample
JP2021505141A (ja
Inventor
アンドリュー ジェイ． マーフィー，
リン マクドナルド，
チュングァン グオ，
ジョン マクウィルター，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2021505141A publication Critical patent/JP2021505141A/ja
Publication of JP2021505141A5 publication Critical patent/JP2021505141A5/ja
Priority to JP2024012752A priority Critical patent/JP7765514B2/ja
Application granted granted Critical
Publication of JP7430636B2 publication Critical patent/JP7430636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1264—DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020530565A 2017-12-05 2018-12-04 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用 Active JP7430636B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024012752A JP7765514B2 (ja) 2017-12-05 2024-01-31 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762594946P 2017-12-05 2017-12-05
US201762594944P 2017-12-05 2017-12-05
US62/594,944 2017-12-05
US62/594,946 2017-12-05
US201762609241P 2017-12-21 2017-12-21
US201762609251P 2017-12-21 2017-12-21
US62/609,241 2017-12-21
US62/609,251 2017-12-21
PCT/US2018/063841 WO2019113065A1 (en) 2017-12-05 2018-12-04 Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024012752A Division JP7765514B2 (ja) 2017-12-05 2024-01-31 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用

Publications (3)

Publication Number Publication Date
JP2021505141A JP2021505141A (ja) 2021-02-18
JP2021505141A5 JP2021505141A5 (enExample) 2022-01-11
JP7430636B2 true JP7430636B2 (ja) 2024-02-13

Family

ID=64734263

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020530565A Active JP7430636B2 (ja) 2017-12-05 2018-12-04 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP2024012752A Active JP7765514B2 (ja) 2017-12-05 2024-01-31 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024012752A Active JP7765514B2 (ja) 2017-12-05 2024-01-31 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用

Country Status (24)

Country Link
US (3) US20210345591A1 (enExample)
EP (3) EP4596688A3 (enExample)
JP (2) JP7430636B2 (enExample)
KR (2) KR20250022220A (enExample)
CN (2) CN111432635B (enExample)
AU (2) AU2018381316B2 (enExample)
BR (1) BR112020011184A2 (enExample)
CA (1) CA3084049A1 (enExample)
DK (2) DK3720279T3 (enExample)
ES (2) ES3035461T3 (enExample)
FI (1) FI4140297T3 (enExample)
HR (2) HRP20221459T1 (enExample)
HU (2) HUE060608T2 (enExample)
IL (2) IL318197A (enExample)
LT (2) LT3720279T (enExample)
MX (2) MX2020005830A (enExample)
PL (2) PL4140297T3 (enExample)
PT (2) PT4140297T (enExample)
RS (2) RS67058B1 (enExample)
SG (1) SG11202003044SA (enExample)
SI (2) SI4140297T1 (enExample)
SM (2) SMT202200448T1 (enExample)
TW (2) TWI827567B (enExample)
WO (1) WO2019113065A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
EP2958937B1 (en) 2013-02-22 2018-08-15 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
CN114502725B (zh) * 2019-07-01 2025-09-12 特里安尼公司 转基因哺乳动物及使用方法
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CN114763558B (zh) * 2021-01-14 2024-02-20 上海泰槿生物技术有限公司 重组基因组、非人哺乳动物细胞及其产生方法和用途
CN118511853A (zh) * 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2015505477A (ja) 2012-02-01 2015-02-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2016534751A (ja) 2013-10-01 2016-11-10 カイマブ・リミテッド 動物モデル及び治療用分子

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
AU8470301A (en) * 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
JP2011501652A (ja) * 2007-09-12 2011-01-13 プロビオドルグ エージー トランスジェニックマウス
ES2445193T3 (es) * 2008-06-27 2014-02-28 Merus B.V. Mamíferos no humanos productores de anticuerpos
WO2010039900A2 (en) * 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
HUE024534T2 (hu) 2011-02-25 2016-01-28 Regeneron Pharma ADAM6 egerek
US10246509B2 (en) 2011-10-17 2019-04-02 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) * 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
PT3597037T (pt) * 2012-06-12 2021-06-01 Regeneron Pharma Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
SG10201808935WA (en) 2013-04-16 2018-11-29 Regeneron Pharma Targeted modification of rat genome
US9738897B2 (en) 2014-06-23 2017-08-22 Regeneron Pharmaceuticals, Inc. Nuclease-mediated DNA assembly
ES2731437T3 (es) 2014-11-21 2019-11-15 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2015505477A (ja) 2012-02-01 2015-02-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｌドメインを含む重鎖を発現するヒト化齧歯動物
JP2016534751A (ja) 2013-10-01 2016-11-10 カイマブ・リミテッド 動物モデル及び治療用分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENTOLILA, LA et al.，Constitutive Expression of Terminal Deoxynucleotidyl Transferase in Transgenic Mice Is Sufficient for N Region Diversity to Occur at Any Ig Locus Throughout B Cell Differentiation，The Journal of Immunology，1997年，Vol. 158, No. 2，pp. 715-723
松本隆志，ヒト抗体の開発と応用はどこまで進んでいるか，化学と生物，1998年，Vol. 36, No. 7，pp. 448-456

Also Published As

Publication number Publication date
LT3720279T (lt) 2022-10-25
EP4140297A1 (en) 2023-03-01
HRP20221459T1 (hr) 2023-01-20
EP3720279B1 (en) 2022-09-21
PT3720279T (pt) 2022-10-06
US12356967B2 (en) 2025-07-15
CN111432635A (zh) 2020-07-17
KR102760506B1 (ko) 2025-02-04
FI4140297T3 (fi) 2025-07-10
EP4596688A2 (en) 2025-08-06
IL274797B2 (en) 2025-06-01
HUE071852T2 (hu) 2025-09-28
HUE060608T2 (hu) 2023-03-28
JP7765514B2 (ja) 2025-11-06
IL274797B1 (en) 2025-02-01
BR112020011184A2 (pt) 2020-11-17
KR20250022220A (ko) 2025-02-14
US20210292439A1 (en) 2021-09-23
TWI827567B (zh) 2024-01-01
RU2020118699A3 (enExample) 2022-04-07
AU2018381316B2 (en) 2025-06-26
PL3720279T3 (pl) 2023-01-16
MX2024004496A (es) 2024-05-08
MX2020005830A (es) 2020-08-20
SMT202500277T1 (it) 2025-09-12
JP2024036440A (ja) 2024-03-15
EP3720279A1 (en) 2020-10-14
US20210345591A1 (en) 2021-11-11
KR20200093570A (ko) 2020-08-05
US20190223418A1 (en) 2019-07-25
ES2928995T3 (es) 2022-11-24
DK4140297T3 (da) 2025-06-23
RU2020118699A (ru) 2022-01-10
EP4596688A3 (en) 2025-11-12
IL274797A (en) 2020-07-30
HRP20250920T1 (hr) 2025-09-26
AU2018381316A1 (en) 2020-04-23
ES3035461T3 (en) 2025-09-03
CN111432635B (zh) 2022-10-21
WO2019113065A1 (en) 2019-06-13
PT4140297T (pt) 2025-07-09
PL4140297T3 (pl) 2025-08-25
RS67058B1 (sr) 2025-08-29
DK3720279T3 (da) 2022-10-24
LT4140297T (lt) 2025-07-25
SMT202200448T1 (it) 2023-01-13
TW201938019A (zh) 2019-10-01
JP2021505141A (ja) 2021-02-18
RS63772B1 (sr) 2022-12-30
TW202438676A (zh) 2024-10-01
SI3720279T1 (sl) 2022-11-30
US11051498B2 (en) 2021-07-06
EP4140297B1 (en) 2025-05-21
IL318197A (en) 2025-03-01
CA3084049A1 (en) 2019-06-13
AU2025204547A1 (en) 2025-07-10
SI4140297T1 (sl) 2025-08-29
CN116058333A (zh) 2023-05-05
SG11202003044SA (en) 2020-04-29

Similar Documents

Publication Publication Date Title
JP7430636B2 (ja) 操作された免疫グロブリンラムダ軽鎖を有する非ヒト動物及びその使用
JP7386292B2 (ja) 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
TW202110323A (zh) 具有表現自κ 基因座的有限λ 輕鏈組庫的非人類動物及其用途
JP2024019660A (ja) 免疫グロブリン重鎖コーディング配列におけるｄｈ－ｄｈ再構成が可能な非ヒト動物
RU2778410C2 (ru) Животные, не являющиеся человеком, имеющие сконструированную легкую цепь лямбда иммуноглобулина, и их применение
RU2843837C2 (ru) Отличные от человека животные, имеющие ограниченный репертуар легких лямбда-цепей, экспрессируемый из локуса капли, и их применение
HK40089251B (en) Mice having an engineered immunoglobulin lambda light chain and uses thereof
HK40089251A (en) Mice having an engineered immunoglobulin lambda light chain and uses thereof
HK40030374B (en) Mice having an engineered immunoglobulin lambda light chain and uses thereof
HK40030374A (en) Mice having an engineered immunoglobulin lambda light chain and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231127

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240131

R150 Certificate of patent or registration of utility model

Ref document number: 7430636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150